VIRAX BIOLABS GROUP LTD (VRAX) Stock Price, Forecast & Analysis
USA - NASDAQ:VRAX - KYG9495L1251 - Common Stock
VRAX Key Statistics, Chart & Performance
The current stock price of VRAX is 0.481 USD. In the past month the price decreased by -26.25%. In the past year, price decreased by -76.07%.
VRAX Latest News, Press Relases and Analysis
VRAX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| MCK | MCKESSON CORP | 23.49 | 105.97B | ||
| COR | CENCORA INC | 22.56 | 69.93B | ||
| CAH | CARDINAL HEALTH INC | 22.86 | 48.39B | ||
| HSIC | HENRY SCHEIN INC | 14.92 | 8.72B | ||
| AHCO | ADAPTHEALTH CORP | 29.69 | 1.29B | ||
| OMI | OWENS & MINOR INC | 2.47 | 245.62M | ||
| WGRX | WELLGISTICS HEALTH INC | N/A | 58.41M |
Related stock screener links
About VRAX
Company Profile
Virax Biolabs Group Ltd. is a holding company, which engages in the sale, distribution, and marketing of diagnostics test kits and med-tech and personal protective equipment products for the prevention, detection, diagnosis, and risk management of viral diseases with a particular interest in the field of immunology. The firm is engaged in developing ViraxImmune with the intention of providing an immunology profiling platform that assesses each individual’s immune risk profile against global viral diseases as well as helping with the early diagnosis of post-viral syndromes associated with T cell exhaustion and chronic inflammation. Its product portfolio includes ViraxClear and ViraxVet. ViraxClear offers a range of accurate diagnostic testing kits and machines. ViraxVet offers various rapid and molecular tests for small animal veterinary diagnostics. The firm is initially focused on diseases associated with post-viral syndromes, including SARS-CoV-2, Human Papillomavirus (HPV), Malaria, Hepatitis B, and Herpes (HSV-1).
Company Info
VIRAX BIOLABS GROUP LTD
Biocity Glasgow, Bo'ness Road, Newhouse
London GB
Employees: 19
Phone: 4402077887414
VIRAX BIOLABS GROUP LTD / VRAX FAQ
Can you describe the business of VIRAX BIOLABS GROUP LTD?
Virax Biolabs Group Ltd. is a holding company, which engages in the sale, distribution, and marketing of diagnostics test kits and med-tech and personal protective equipment products for the prevention, detection, diagnosis, and risk management of viral diseases with a particular interest in the field of immunology. The firm is engaged in developing ViraxImmune with the intention of providing an immunology profiling platform that assesses each individual’s immune risk profile against global viral diseases as well as helping with the early diagnosis of post-viral syndromes associated with T cell exhaustion and chronic inflammation. Its product portfolio includes ViraxClear and ViraxVet. ViraxClear offers a range of accurate diagnostic testing kits and machines. ViraxVet offers various rapid and molecular tests for small animal veterinary diagnostics. The firm is initially focused on diseases associated with post-viral syndromes, including SARS-CoV-2, Human Papillomavirus (HPV), Malaria, Hepatitis B, and Herpes (HSV-1).
Can you provide the latest stock price for VIRAX BIOLABS GROUP LTD?
The current stock price of VRAX is 0.481 USD. The price decreased by -3.86% in the last trading session.
Does VRAX stock pay dividends?
VRAX does not pay a dividend.
How is the ChartMill rating for VIRAX BIOLABS GROUP LTD?
VRAX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Which stock exchange lists VRAX stock?
VRAX stock is listed on the Nasdaq exchange.
Can you provide the PE ratio for VRAX stock?
VIRAX BIOLABS GROUP LTD (VRAX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.65).
VRAX Technical Analysis
VRAX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to VRAX. While VRAX seems to be doing ok healthwise, there are quite some concerns on its profitability.
VRAX Financial Highlights
Over the last trailing twelve months VRAX reported a non-GAAP Earnings per Share(EPS) of -1.65. The EPS increased by 50.82% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -94.31% | ||
| ROE | -106.41% | ||
| Debt/Equity | 0.06 |
VRAX Forecast & Estimates
For the next year, analysts expect an EPS growth of 166.67% and a revenue growth 66.97% for VRAX